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Abstract
Glucose-6-phosphate dehydrogenase deficiency (G6PDd) is the most common enzymopa-
thy globally, and deficient individuals may experience severe hemolysis following treatment
with 8-aminoquinolines. With increasing evidence of Plasmodium vivax infections through-
out sub-Saharan Africa, there is a pressing need for population-level data at on the preva-
lence of G6PDd. Such evidence-based data will guide the expansion of primaquine and
potentially tafenoquine for radical cure of P. vivax infections. This study aimed to quantify
G6PDd prevalence in two geographically distinct areas in Sudan, and evaluating the perfor-
mance of a qualitative CareStart rapid diagnostic test as a point-of-care test. Blood samples
were analyzed from 491 unrelated healthy persons in two malaria-endemic sites in eastern
and central Sudan. A pre-structured questionnaire was used which included demographic
data, risk factors and treatment history. G6PD levels were measured using spectrophotom-
etry (SPINREACT) and first-generation qualitative CareStart rapid tests. G6PD variants
(202 G>A; 376 A>G) were determined by PCR/RFLP, with a subset confirmed by Sanger
sequencing. The prevalence of G6PDd by spectrophotometry was 5.5% (27/491; at 30% of
adjusted male median, AMM); 27.3% (134/491; at 70% of AMM); and 13.1% (64/490) by
qualitative CareStart rapid diagnostic test. The first-generation CareStart rapid diagnostic
test had an overall sensitivity of 81.5% (95%CI: 61.9 to 93.7) and negative predictive value
of 98.8% (97.3 to 99.6). All persons genotyped across both study sites were wild type for the
G6PD G202 variant. For G6PD A376G all participants in New Halfa had wild type AA
(100%), while in Khartoum the AA polymorphism was found in 90.7%; AG in 2.5%; and GG
in 6.8%. Phenotypic G6PD B was detected in 100% of tested participants in New Halfa
while in Khartoum, the phenotypes observed were B (96.2%), A (2.8%), and AB (1%). The
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African A- phenotype was not detected in this study population. Overall, G6PDd prevalence
in Sudan is low-to-moderate but highly heterogeneous. Point-of-care testing with the qualita-
tive CareStart rapid diagnostic test demonstrated moderate performance with moderate
sensitivity and specificity but high negative predicative value. The two sites harbored primar-
ily the African B phenotype. A country-wide survey is recommended to understand GP6PD
deficiencies more comprehensively in Sudan.
Author summary
Malaria is caused by five species of parasites; of these Plasmodium falciparum and P. vivax
cause the majority of global morbidity and mortality. Plasmodium vivax infection is an
emerging public health problem in sub-Saharan Africa, including Sudan. Primaquine and
other 8-aminoquinolines including tafenoquine are the primary treatments to target the
silent liver stage (hypnozoites) in P. vivax infections. However, these regimens can cause
severe intravascular hemolysis in patients suffering from glucose-6-phosphate dehydroge-
nase deficiency (G6PDd). To support safe and efficacious use of primaquine, and poten-
tially tafenoquine in Sudan, this study aimed to estimate the prevalence of G6PDd across
two sites in Sudan using spectrophotometry and a qualitative CareStart rapid diagnostic
test. Subsequent genetic analysis by PCR/RFLP and sequencing of G6PD genetic variants
was performed. This survey found an overall prevalence was 5.5% (27/491; 30% of
adjusted male median, AMM), and 27.3% (134/491; 70% of AMM) and 13.1% (64/490) by
qualitative CareStart rapid diagnostic test. Important differences in distribution of genetic
variants of G6PD were found across the two sites, and the African A- was not observed. In
univariate analysis a few parameters showed significant association with G6PD deficiency.
In conclusion the prevalence of G6PDd was low to moderate but heterogonous, and the
first-generation qualitative CareStart rapid diagnostic test showed moderate performance
in both males and females.
Introduction
The Republic of Sudan has an extensive malaria burden with an estimated 1,600,000 cases
(95% CI, 904,000 to 3,686,000) and approximately 5,000 deaths in 2018 [1]. Of this reported
case total, approximately 1,300,00 (79.6%) were infections with Plasmodium falciparum;
140,000 (8.8%) were infections with P. vivax, and 190,000 (11.6%) were co-infections with P.
falciparum and P. vivax [1]. A recent study from ten states across Sudan reported a prevalence
of P. vivax in clinical malaria cases of 26.6% by PCR [2].
Sudan’s national malaria control program is focused on malaria elimination, with insecti-
cide-treated bed nets (ITN) as the primary preventive intervention, combined with indoor-
residual spraying (IRS) in conjunction with early diagnosis and treatment [3]. In Sudan a
14-day primaquine regimen (0.25 mg/kg day) is currently used for a radical cure of P. vivax
infection. To date, reports originating from Sudan on glucose-6-phosphate dehydrogenase
deficiency (G6PDd) are limited [4–6]. The G6PD gene consists of 13 exons and 12 introns,
which are located on the long arm of the X-chromosome at gene loci Xq28. More than 200
mutations have been reported [7], most of which are due to single nucleotide substitution [8].
The most common mutations across Sub-Sahara Africa are G6PD A− (202A/376G) and
G6PD A (202G/376G or 202A/376A), both of which are characterized by a reduction in
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enzyme activity [9]. In diverse global settings including Southern Europe, the Middle East,
India, Papua New Guinea, and Iran theG6PD–Mediterranean variant (Med, C563T) is preva-
lent [5]. Globally, the most common wild type of the variant is G6PD�B (202G/376A), which
exhibits normal enzyme activity and is present in the worldwide population [10]. While the
G6PD enzyme has been well-studied in specific regions, large gaps remain, especially toward
establishing an evidence-base for use of primaquine and other 8-aminoquinolines in control
and elimination programs.
A major barrier to sustained control and elimination of P. vivax infections is the existence
of hypnozoites (a quiescent parasite life stage) that remain dormant and undetectable in the
host’s liver tissue [11]. When these hypnozoites are reactivated by poorly-understood mecha-
nisms, they can re-establish infections weeks or months later [12–14]. Current WHO guide-
lines for malaria programs are based on the use of primaquine to target hypnozoites; however,
routine wide-scale use of a 14-day regimen for a radical cure necessitates G6PD testing when-
ever possible [15].
There are currently no laboratory or molecular methods to confirm carriage of hypnozoites.
Therefore, treatment of symptomatic cases or mass drug administration is required to clear
the hypnozoite reservoir. However, the relative risks of P. vivax infection in comparison to
potential hemolytic harm from 8-aminoquinoline therapy are conditional on local endemicity
and severity of local G6PD variants [16].
Primaquine and other 8-aminoquinolines have the potential to cause hemolysis that may
range from mild and self-limiting, all the way to severe and requiring transfusion [17]. The
WHO has developed a classification scheme for G6PD deficiencies which consists of four
broad classes: class I (severe mutation); class II (intermediate mutation, 10% of normal G6PD
function); class III (mild mutation, 10–60% of normal G6PD function); and class IV (asymp-
tomatic, 60–100% of normal G6PD function). However, recent studies have suggested that
these classes are broad and may be insufficient to accurately capture the diversity of G6PD
enzymopathy, especially in females [15]. Although the need for G6PD testing before prima-
quine administration has been recognized, the health system in Sudan does not currently inte-
grate G6PD testing into the malaria control program [18]. To address these challenges, and
maximize the impact of the limited health budgets, there is a pressing need to measure and
understand the prevalence of the well-described G6PDd alleles. To support these efforts, indi-
viduals who presented to clinics in two diverse malaria-endemic settings in Sudan were tested
using biochemical and molecular methods. Additionally, the performance of first-generation
qualitative CareStart G6PD rapid diagnostic tests (RDT) were evaluated for the screening of
G6PD deficiency in point-of-care (POC) settings.
Methods
Ethics statement
This study received an ethical clearance from the Ethical Committee of Institute of Endemic
Diseases, University of Khartoum (approval number: IRB/IEND 1/2014; date 10/6/2014).
Written informed consent was signed by each study subject (adults) or guardians (children).
UMass IRB determined the analysis of this study was exempt from human subject review
(determination #1798; Jan. 2020).
Study areas
This cross-sectional survey was conducted in two malaria-endemic areas in Sudan (Fig 1)
from February to May of 2015. The first site was Gezira Slanj, rural Khartoum, in central
Sudan (15˚53011.2@N 32˚31039.9@E), where malaria transmission is seasonal. Two annual peaks
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of transmission occur in this area: one following the rainy season (July-October) while the
other occurs during the temperate months (December-February). The second site was New
Halfa town, in Eastern Sudan (15˚200N 35˚35000@E). There is mesoendemic malaria transmis-
sion in this region, with a single peak during the rainy season (July-October). Both study sites
are co-endemic for P. falciparum and P. vivax [2,4].
Study population, study power and sampling strategy
The study population consisted of apparently healthy subjects who were accompanying
patients attending primary health units within the study areas. Women who were pregnant or
lactating, and all persons seeking care were excluded. Convenience sampling was used to invite
participants to give informed consent to participate in the study. The study was powered for
an assumed G6PD prevalence of 10%; a sample size of 450 inclusions provides a 95% CI of 7.4
to 13.1% (binomial exact), providing sufficient precision to inform policy and future research.
Fig 1. Location of G6PD study sites, 2015, Sudan. Map produced in QGIS [QGIS Development Team, 2021. QGIS Geographic Information
System. Open-Source Geospatial Foundation. http://qgis.org]; basemaps [https://www.diva-gis.org/Data] and [Flanders Marine Institute (2021):
MarineRegions.org. Available online at www.marineregions.org. Consulted on 2021-08-21].
https://doi.org/10.1371/journal.pntd.0009720.g001
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A total of 557 subjects were recruited across both study sites. Essential demographic charac-
teristics were collected using a structured questionnaire, including basic demographic data,
linguistic group, education, occupation, medical history, blood transfusion history, and
detailed drug history, including adverse drug reactions. Venous blood samples were collected
in EDTA and heparin tubes using aseptic conditions. The EDTA samples were subsequently
used for hemoglobin estimation and DNA extraction, while the heparin-preserved samples
were used for G6PD activity measurement within 30 minutes of blood collection.
G6PD activity measurement and qualitative CareStart point of care (POC)
testing
The gold standard biochemical G6PD measurements was collected according to published
methods [19]; using a SPINREACT kit with spectrophotometric reading at 340nm and 25˚C
(BioSystems BTS 310) to measure G6PD activity in heparinized venous blood, as per manufac-
turer instructions. Normal and deficient G6PD controls provided with the kit were run daily
prior to all clinical sample measurements (Ref: 100 252 0, SPINREACT, Spain).
The CareStart G6PD point-of-care tests (Access Bio, Catalog # G0221; 2014 version) were
performed according to the manufacturer instructions [20]. This is a qualitative test, providing
either normal (purple) or a deficient (colorless) result. The spectrophotometry and CareStart
tests were performed by two independent readers who were blinded to all other results. All
sample analyses were performed within 30 minutes of blood collection. Extreme readings were
recorded but not re-analyzed, and addressed in the statistical analysis.
G6PD population-level activity
In this study the adjusted male median (AMM) activity of enzyme activity was used as the ref-
erence cutoff value for the determination of deficiency status within the study population [19].
Briefly, the population reference value was defined as the population median after removal of
all males with measured activity <10% of the median; and an activity cutoff of<30% of this
adjusted male median was used to define G6PDd in this population as a whole [19]. A more
stringent cutoff at<70% of the AMM was also evaluated to support potential tafenoquine
implementation.
DNA extraction and G6PD variants genotyping
DNA extraction was performed using the standard phenol-chloroform method [21], and gen-
otyping was conducted according to previously published methods [22] with some minor
modification in annealing temperature of PCR. PCR was performed for exons 4 and 5 of the
G6PD gene using previously published primers [22]. Briefly, PCR reactions were performed in
total volume of 20 μl containing genomic DNA, 10pmol of the primers and PCRPreMix (i-Taq
Intron Biotechnology, South Korea) with a thermocycler(SensQuick Inc., Germany). The
adjusted annealing temperatures were 61.3˚ C and 60.3˚ C for the G6PD exon 4 and exon 5,
respectively.
PCR products (5 μl) were digested with 1 U of NlaIII and FokI endonucleases (New
England BioLabs Inc., UK) for (G6PD G202A) and (G6PD G376A) and incubated at 37˚C
overnight, analyzed on 2% agarose gel and visualized using a gel documentation system (BDA
compact, Biometra, Germany). Restriction fragment length polymorphism (RFLP) results
were confirmed by commercial DNA sequencing of exons 4 and 5 (Macrogen Inc, Nether-
lands) on a subset 60 samples, chosen to represent diverse PCR/RFLP patterns.
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Statistical analysis
The population-level values for G6PD activity were compared using k-sample nonparametric
median tests, and summarized as medians due to non-normal distributions, with bootstrapped 95%
CIs. Categorical variables were compared using χ2 tests. The adjusted male median breakpoint for
G6PDd was determined using the method of< 30% (or<70% where indicated) enzyme activity of
the adjusted male median [23]. Logistic models were used to assess factors associated with G6PDd,
from surveyed questionnaire items. These factors were examined using univariable models; all fac-
tors significant at p< 0.20 were taken forward to multivariable models; Akaike and Bayesian Infor-
mation Criteria (AIC/BIC) were used to assess model parsimony. Logistic regression model fit was
assessed using the le Cessie-van Houwelingen-Copas-Hosmer unweighted sum of squares test and
Tjur’s R2 [24,25]. Analyses were performed with Stata 14 or 16 (College Station, TX; USA) and R
software [26]; all tests were two-sided, with α = 0.05. While these data had generally low levels of
missing values, multiple imputation (MI) was used to ensure robust results, and to minimize poten-
tial biases from complete-case analysis in logistic regression. All risk factors significant at p< 0.20
were imputed using MI via chained equations, using data augmentation for variables that exhibited
complete separation with a total of 50 imputations. Adequacy of the imputed datasets was assessed
using standard recommendations [26]. Age was missing for a single observation, which led to insta-
bility in multiple imputations, and this observation was removed for final models.
Results
A total of 557 persons consented and were enrolled across both study sites. A subset of these
participants had missing timepoints for spectrophotometry, or biologically implausible values
in biochemical testing. These 66 individuals (32 females, and 34 males), did not differ from the
overall study population by sex, (p = 0.67; χ2 test), but were all hospital cases at one of the sites
(both χ2 tests, p < 0.001). Due to missing outcome data, these were removed from further
analysis, providing a final study population of 491 persons. The overall population attributes
and selected survey are presented in Table 1. Detailed population characteristics and other sur-
vey responses can be found in the Supplemental information (S1 Table).
Biochemical testing
The measured G6PD activities for both sites by spectrophotometry are presented in Table 2.
Recorded values ranged from 0.22 to 13.0 U/g Hb, with a median of 4.27 (95% CI: 3.95 to 4.59)
U/g Hb. There was a statistically significant difference in median enzyme activity by study site
(p< 0.001); but not by sex (p = 0.89), using a nonparametric k-means test (Table 2). The dis-
tributions of measured activities are shown by study site (Fig 2) and by sex (Fig 3). From these
measurements, the corresponding population adjusted male median value was 4.23 U/g Hb.
Of the 491 subjects, 27 subjects (5.5%; 95% CI: 3.7 to 7.9) had severe or moderately severe
G6PDd, with a measured enzyme activity <30% of this adjusted male median (1.27 U/g Hb).
Twenty-four of these were from the New Halfa site, including 16 females, while three were
from Khartoum, including two females (Table 3). One individual (a female in Khartoum) had
extremely low activity (< 10% of the AMM). Using the more stringent threshold of70% of
AMM, a total of 134 (27.3%) persons would be classified as G6PDd. (Table 3).
Point-of-care (POC) qualitative rapid test (CareStart) and concordance
with biochemical testing
A total of 491 persons were tested for G6PDd using CareStart POC tests. Of these tests, 490
results were available for analysis; one test gave an invalid reading. A total of 64 subjects
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(13.1%, 95% CI: 10.2 to 16.4%) were G6PDd according to the CareStart test. There were signif-
icant differences by geographical location (p = 0.031) but not by sex (p = 0.258) via χ2 tests.
Using cutoffs of 30% and 70% of the AMM (1.27and 2.96 U/g Hb respectively), the perfor-
mance of RDT compared to the gold-standard test is shown in Table 4 and Fig 4. The overall
sensitivity was moderate at 81.5% (95% CI: 61.9 to 93.7), with comparable values in males and
females (78% vs 83% with wide confidence intervals). No differences were observed in specific-
ity and negative predicative value between male (91% and 99%) and female populations (91%
and 99%).
Factors associated with G6PDd
In bivariate analysis, multiple factors showed a significant association with G6PDd status (less
than 30% AMM), including study site (odds ratio of G6PDd Khartoum relative to New
Halfa = 0.23 (95% CI: 0.07 to 0.79), p = 0.02); data source (public hospital relative to private
clinic, OR = 0.30 (95% CI 0.14 to 0.65), p = 0.002), and any self-reported recent antibiotic use
(OR = 2.43 (95% CI: 1.1 to 5.5), p = 0.031). However, after adjustment for covariates in multi-
variable analysis, the only factor that remained statistically significant was the subject’s weight
Table 1. Study population overview G6PD surveys, New Halfa and Khartoum Sudan, 2015 (N = 491).
Characteristic Value n (% of total)
Study site New Halfa 327 (66.6%)
Khartoum 164 (33.4%)
Missing 0 (-)
Data source Private clinic 125 (25.5%)
Public hospital 360 (73.3%)
Missing 6 (1.2%)
Sex Female 252 (51.3%)
Male 239 (48.7%)
Missing 0 (-)
Age, mean (SD) 34.2 (± 15.6)
Missing 0 (-)
Anemia (any; WHO standards) No 264 (53.8%)
Yes 227 (46.2%)
Missing 0 (-)
Weight in kg, mean (SD) 59.7 (± 18.4)
Missing 7 (1.4%)
Bilirubin in mg/dL, median (IQR) 0.3 (0.1, 0.6)
Missing 0 (-)
Hemoglobin (Hb), mean (SD) 12.5 (± 2.4)
Missing 0 (-)
G6PD activity (U/g Hb) by spectrophotometry, median (95% CI) 4.3 (4.0 to 4.6)
https://doi.org/10.1371/journal.pntd.0009720.t001
Table 2. Summary of G6PD activities (with 95% CIs) by biochemical testing, total study population, and in New Halfa and Khartoum, Sudan.
G6PD activity, U/g Hb (median, 95% CI)
Overall study population (N = 491) New Halfa (n = 327) Khartoum (n = 164)
Total tested population 4.3 (4.0 to 4.6) 3.69 (3.3 to 4.0) 5.0 (4.6 to 5.4)
Males only 4.2 (3.8 to 4.6) 3.8 (3.3 to 4.2) 5.0 (4.6 to 5.5)
Females only 4.3 (3.9 to 4.7) 3.7 (3.2 to 4.1) 4.8 (4.4 to 5.3)
https://doi.org/10.1371/journal.pntd.0009720.t002
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in kilograms, with an adjusted OR of 0.97 (95% CI 0.95 to 0.99; p = 0.01). This indicates that
each kg increased body weight lowers the odds of being G6PD deficient (<30% AMM), by
approximately 3% (See S1 Table).
G6PD genotyping
PCR/RFLP analysis was performed for all 491 enrolled subjects; 397 of which were successfully
amplified for the G6PD gene and met data quality thresholds. Considering the G202Α G6PD
Fig 2. Distribution of G6PD activities in study population, by gender (n = 491).
https://doi.org/10.1371/journal.pntd.0009720.g002
Fig 3. Distribution of G6PD activities in study population, by study site (n = 491).
https://doi.org/10.1371/journal.pntd.0009720.g003
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gene polymorphisms across both study sites, all persons tested were GG homozygotes (100%
GG genotype frequency). For G6PD A376G, the following genotypes were detected: AA
(n = 235; 100%) in New Halfa; AA (n = 147; 90.7%), GG (n = 11; 6.8%), AG (n = 4; 2.5%) in
Khartoum (Table 5).
Among the females examined in New Halfa (n = 122), the G6PD A376G genotype was
entirely AA (100%), whereas the distribution in Khartoum (n = 90) was AA (n = 81; 90%);
GG (n = 5; 5.6%); AG (n = 4; 4.4%) (Table 5); there was a statistically significant difference
in the distribution of A376G polymorphisms by geographic location (p < 0.001; χ2 test). Of
these participants with non-wild-types, the associated G6PD enzyme activities are shown in
Fig 5.
In analysis of the 27 G6PD deficient subjects, 26 carried B variants, and one homozygous
female carried an A variant. In this population, the A- variant was not detected; however, the
Mediterranean variant was not tested for in this study. The genotype of all 27 G6PD deficient
subjects was AA for the G202A polymorphism. For the A376G polymorphism, 26 subjects had
the AA genotype while one subject carried the GG genotype.
Table 3. Prevalence of G6PD deficiency in surveyed populations by biochemical testing (SPINEACT test) (adjusted male median = 4.23 U/g Hb), New Halfa and
Khartoum Sudan, 2015.
Study site Sex Total G6PD deficient 30% of adjusted male median G6PD deficient 70% of adjusted male median
Khartoum F 91 2.2% (95% CI: 0.01 to 7.7) (n = 2) 13.1% (7.0 to 21.9) (n = 12)
M 73 1.4% (0.01 to 7.4) (n = 1) 12.3% (5.8 to 22.1) (n = 9)
New Halfa F 161 9.9% (5.8 to 15.6) (n = 16) 35.4% (28.0 to 43.3) (n = 57)
M 166 4.8% (2.1 to 9.3) (n = 8) 33.7% (26.6 to 41.5) (n = 56)
Total 491 5.5% (2.7 to 63) (n = 27) 27.3% (23.4 to 31.4) (n = 134)
https://doi.org/10.1371/journal.pntd.0009720.t003
Table 4. Concordance between biochemical testing and qualitative CareStart results, New Halfa and Khartoum
Sudan.
Biochemical testing (30% of adjusted male median)
CareStart qualitative result Deficient Not deficient total
Deficient 22 42 64
Not deficient 5 421 426
total 27 463 490
Overall (N = 490) Percent (95% CI)
Sensitivity 81.5% (61.9–93.7); Specificity90.9% (87.9–93.4); PPV 34.4% (22.9–47.3); NPV 98.8% (97.3–99.6).
Males only (n = 239)
Sensitivity 77.8% (40.0–97.2); Specificity 91.3% (86.9–94.6); PPV 25.9% (11.1–46.3); NPV 99.1% (96.6–100).
Females only (n = 251)
Sensitivity 83.3% (58.6–96.4); Specificity 90.6% (86.1–94.0); PPV 40.5% (24.8–57.9); NPV 98.6% (96.0–99.7).
Biochemical testing (70% of adjusted male median)
CareStart qualitative result Deficient Not deficient total
Deficient 31 33 64
Not deficient 103 323 426
total 134 356 490
Overall(N = 490)
Sensitivity 23.1%; (16.3–31.2); Specificity 90.7% (87.2–93.5); PPV 48.4% (35.8–61.3); NPV 75.8% (71.5–79.8).
Males only (n = 239)
Sensitivity 16.9%; (8.8–28.3); Specificity 90.8% (85.5–94.7); PPV 40.7% (22.4–61.2); NPV 74.5% (68.1–80.2).
Females only (n = 251)
Sensitivity 29.0%; (18.7–41.2); Specificity 90.7% (85.5–94.5); PPV 54.1% (36.9–70.5); NPV 77.1% (70.9–82.6).
https://doi.org/10.1371/journal.pntd.0009720.t004
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Discussion
Sudan’s national malaria control program is focused on malaria elimination with insecticide-
treated bed nets (ITN) as the primary preventive intervention. ITN is combined with indoor
residual spraying and early diagnosis and treatment, mainly with artemisinin-based combina-
tion therapies (ACTs). Reducing the burden of malaria from P. falciparum (single low-dose),
and P. vivax may require expansion of primaquine use. However, there is very limited evi-
dence-based data on the safety of such health programs for patients with G6PDd. While exten-
sive studies have been done throughout Southeast Asia to examine the prevalence and
diversity of G6PD deficiencies [27], studies reporting data from Africa are emerging and lim-
ited. Studies to date have assessed G6PD in Ghana [28], Mauritania [29], Eritrea [30], and
Ethiopia [31,32]. However, there have been no detailed studies from Sudan.
This study reported the frequencies of G6PDd in two sites, their genotypic and phenotypic
characterization, and the results of evaluation of a qualitative POC test. The overall G6PDd
Fig 4. Distribution of G6PD activities, by CareStart results (n = 490).
https://doi.org/10.1371/journal.pntd.0009720.g004
Table 5. Comparison of genotypic data by study site, Sudan (n = 397). (note: WT = wild type).
Sex Genotype Phenotype Label Interpretation G6PD Activity, U/g Hb Median (95% CI) New Halfa n = 235(%) Khartoum n = 162 (%)
M 202G/376A B Hemizygous WT 4.1 (3.5–4.6) 113 (48.1) 66 (40.7)
202G/376G A Hemizygous A 4.8 (3.7–5.9) 0 (0.0) 6 (3.7)
202A/376A - 0 (0.0) 0 (0.0)
202A/376G A- Hemizygous A- - 0 (0.0) 0 (0.0)
F 202G, 202G/376A, 376A B/B Homozygous WT 4.3 (3.9–4.7) 122 (51.9) 81 (50.0)
202A, 202G/376A, 376A
202G, 202G/376G, 376A
A/B Heterozygous A 6.8 (4.3–9.4) 0 (0.0) 4 (2.5)
202G, 202G/376G, 376G
202A, 202A/376A, 376A
A/A Homozygous A 4.7 (1.7–7.6) 0 (0.0) 5 (3.1)
202A, 202G/376G, 376A A-/B Heterozygous A- - 0 (0.0) 0 (0.0)
202A, 202A/ 376G, 376G A-/A- Homozygous A- - 0 (0.0) 0 (0.0)
https://doi.org/10.1371/journal.pntd.0009720.t005
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prevalence was estimated at 5.5% by the spectrophotometry with significantly higher preva-
lences New Halfa. This likely related to a differing ethnic composition of the population in
New Halfa [33]. This reported G6PDd prevalence is considered “moderate” according to
WHO standards [34]. Testing with the CareStart POC test provided a higher estimated preva-
lence, which is consistent with other studies [35–38]. Earlier reports of G6PD in Sudan focused
on enzyme isoforms only, but did not provide associated frequencies [6,39]; and a recent study
conducted in Northern Sudan reported on polymorphic genetic variants of the enzyme [5].
The reported prevalence in the current study is broadly consistent with results from Ethio-
pia, Egypt and Eritrea [31,40,30]. However, this G6PDd prevalence is lower than those
reported from West African settings, including Senegal (12%) [41], Sierra Leone (11.3%) [42]
and Burkina Faso (9.3%) [43]. The qualitative CareStart test performed moderately well in this
study compared with the reference method. This is in concordance with previous reports from
Cambodia [35], Philippines [36], Ghana [37], and Indonesia [38]. These results highlight some
limitations in the qualitative CareStart test for the detection of persons with low or moderate
enzyme levels, with a sensitivity of 82%. We did not observe any major differences between
performance in males and females, as has been observed in other studies, e.g. Cambodia [35].
The limitations of non-quantitative test for screening of females occurs heterozygous females
produce heterogeneous levels of the enzyme (“Lyonization”). This heterogeneity is due to ran-
dom activation of one X-chromosome during embryogenesis, resulting in varying proportions
of deficient and normal red blood cells in different heterozygotes females, which ultimately
leads to a range of observed G6PD activities ranging from very low to near normal levels [20].
These findings agree with the field evaluation of G6PD CareStart RDT in Cambodians [35]. In
the present study, the moderate sensitivity of CareStart POC as a qualitative test may not be
adequate for diagnosis for G6PDd in these populations. The present study found that the only
factor associated with G6PD activity in adjusted models was bodyweight in kg, with an
adjusted OR of 0.97 (95% CI: 0.95 to 0.99), p = 0.01). While similar associations have been
found in murine models [44], this finding is likely of limited public health utility.
Fig 5. Distribution of G6PD activities, by genotyping results (n = 397).
https://doi.org/10.1371/journal.pntd.0009720.g005
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The most common G6PD phenotypic variant in this study was G6PD B (96.2%, 382/397)
which is consistent with results from a previous study in northern Sudan [5]. Similarly, other
reports from Eritrea and Burkina Faso showed a high frequency of the G6PD B variant (87.5%
and 74.5%, respectively) [30,43]. Lower frequencies of the B variant were reported in surveys
from Sierra Leone, Ghana, and Cameroon [45]. The African variant (A) was detected in
(2.8%), 11/397) of the study subjects, which is consistent with a previous study from northern
Sudan which reported that among 207 participants, 90.3% carried the B variant, 1.4% carried
the A; and 8.3% were not assigned a phenotype.[5]. The current study found the G6PD AB var-
iant was present in a limited number of study subjects (1.0%; 4/397), all of which were female.
Finally, we found no evidence for the G6PD A- isoform, in agreement with other studies in
Sudan and recent reports from Eritrea [30], and Ethiopia [32]. Similar to the prevalence of
G6PDd, the genetic variants also showed significant variation between the two study sites
which may be related to different ethnic composition of these populations.
The 27 deficient subjects also suggest that G6PD B is the most prevalent variant in this sam-
pled population, and the single A variant was a homozygous female. However, this study can-
not exclude the presence of the Mediterranean and other variants which may co-exist with the
ones reported here, and further surveys are required to capture the full diversity of G6PD vari-
ants in Sudanese populations.
As expected, there were large differences in measured enzyme activity by the genotype of
males (hemizygous) and females (homozygous and heterozygous), as were differences in the
distribution of the enzyme activity in the females, with heterozygous females having values
ranging from low to normal enzyme activity [20]. However, there are several unusual features
of the measured enzyme activities in this study. Specifically, the male population does not
show the expected bimodal distribution as observed in most other settings [46,47], and sur-
prisingly, a greater number of G6PDd women than G6PDd men were detected in biochemical
testing. Few published results have appeared with the spectrophotometric test kit used in this
study, which also required temperature adjustment as per manufacturer instruction. Together,
these unusual findings suggest a critical role for follow up studies to understand this complex
array of biochemical results.
In conclusion, this study provides the first large-scale data on the prevalence of G6PDd,
and associated enzymatic activity and predictors in individuals by using phenotypic and
molecular tests in endemic areas of P. vivax malaria in Central and Eastern parts of Sudan.
The most common G6PD phenotypic variant in this study was B including the deficient sub-
jects with absence of A-. The limited number of severely deficient G6PD activities across these
two study sites (one female), suggests hemolysis risks may be somewhat limited at a popula-
tion-level where milder variants predominate [48]. The lack of a clear association between
genotype and measure enzyme activity warrants further verification with more diverse samples
from other sites, and with more detailed genotyping. Other additional genetic variants that
were not analyzed in this study may also have important associations with G6PD deficiencies
in Sudan.
It should be emphasized that Sudan was highlighted as an area with unusually large uncer-
tainty in earlier statistical models, and these estimates were based on the landmass before the
independence of South Sudan. The impact of this areal unit problem is difficult to assess, and
this current study greatly expands the evidence-based for G6PD-related policy in Sudan.
The use of primaquine within the public health sector in Sudan is a national policy. How-
ever, access is limited in some areas, which is a common scenario in many vivax-endemic
countries [49].
Results from this study highlight the heterogeneity of G6PD level in the Sudanese popula-
tion, and the good performance of the CareStart test for detection of moderate-to-severe
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G6PD deficiency. Important gaps remain to ensure safe and routine radical cure of P. vivax
infections towards the Sudanese Ministry of Health’s malaria elimination goals.
In conclusion, based upon data from these two sites, the prevalence of G6PDd using the
30% AMM is somewhat lower than previous estimates. However, larger population-based
studies and operational research on the use of point-of-care G6PD testing are needed to ensure
the safe use of primaquine and potentially tafenoquine in diverse Sudanese populations.
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